Imeik Technology Development Co Ltd
SZSE:300896
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Imeik Technology Development Co Ltd's latest stock split occurred on Apr 29, 2024
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, Imeik Technology Development Co Ltd traded at 297.01 per share. Afterward, the share price was about 217.8.
The adjusted shares began trading on Apr 29, 2024. This was Imeik Technology Development Co Ltd's 2nd stock split, following the previous one in Mar 16, 2021.
Global
Stock Splits Monitor
Imeik Technology Development Co Ltd
Glance View
Imeik Technology Development Co Ltd is a prominent player in the cosmetic medical industry, a sector that has experienced robust growth fueled by rising consumer demand for aesthetic enhancements. Situated in the heart of the beauty-conscious market of China, Imeik specializes in the development, manufacturing, and commercialization of medical aesthetic products, most notably hyaluronic acid fillers. These products, used extensively by dermatologists and beauty clinics, cater to individuals seeking non-invasive procedures to enhance their aesthetic appeal. By leveraging advanced biotechnological methodologies, Imeik has positioned itself as a trusted brand, gaining an edge through continual innovation and adherence to rigorous safety standards. The company's business model revolves around the strategic development and distribution of a diversified portfolio of aesthetic products. Imeik's revenue streams principally derive from the commercialization of its cutting-edge dermal fillers and other complementary medical solutions. By focusing on research and development, the company not only stays ahead of aesthetic trends but also ensures that its offerings maintain a high standard of efficacy and safety, essential in a sensitive market domain like medical aesthetics. Furthermore, Imeik’s collaborations with key stakeholders in the healthcare and cosmetic sectors amplify its reach, solidifying its market position and driving sustainable profitability. Through these endeavors, Imeik effectively captures a slice of the lucrative and rapidly growing beauty market, reinforcing its leadership within the industry.
2695
1961
HYT
1436
334A